Highest-materiality recent filing
All 11 incumbent directors re-elected with overwhelming support (over 98% for each nominee).
ABVC BioPharma concludes Q3 2025 financials unreliable; total assets surge 179% to $21.06M
Board determined Q3 2025 financials unreliable due to revenue recognition errors ($795,950 reversed) and land valuation error ($798,486 increase).
ABVC BioPharma completes $2.28M additional unregistered offering, issues 1.5M shares
From May 26, 2025 to Jan 6, 2026, ABVC accepted additional subscriptions totaling $2,275,468 under same terms as prior Reg S offering.
ABVC BioPharma Q3 2025 licensing revenue up 230% YoY to $1.28M; total assets rise 181%
Licensing revenue of $1.28M in Q3 2025 vs $0.39M in Q3 2024 (+230% YoY).
ABVC BioPharma approves performance incentive plan contingent on $1B market cap by Dec 31, 2027
Plan grants up to 1% of outstanding shares, capped at $10M total and $1M per recipient.
ABVC Biopharma: Former auditor WWC refused to provide letter agreeing with 8-K statements
WWC, P.C. agreed not to renew engagement on October 10, 2024.
ABVC BioPharma reports Q2 2025 results with 103% asset growth and $350K licensing revenue
Total consolidated assets increased 103% to $16.2 million from $8.0 million in Q2 2024
ABVC issues 2.04M shares + 1M warrants for Taiwan land from director Shuling Jiang
Issued 2,035,136 restricted shares to Jiang for land valued at $3.86M, plus assumption of $500K bank liability.
ABVC BioPharma shareholders approve all four proposals including related-party land deal
11 directors re-elected with ~5.9M votes for each; 18,525 withheld per director.
ABVC BioPharma accepts additional $670K in Reg S offering, issuing 957,144 shares
Initial Reg S offering (Apr 30–May 9) sold 1,030,413 shares for aggregate gross proceeds ~$619,625.
ABVC BioPharma regains Nasdaq minimum bid price compliance; reports 234% revenue growth in FY2024
Regained compliance after maintaining $1.00 bid price for 10 consecutive days through May 12, 2025.
ABVC BioPharma raises ~$619k via unregistered share sales to non-U.S. persons
On April 30, 2025 sold 724,372 shares for ~$436k to 15 non-U.S. persons under Regulation S.
ABVC BioPharma regains Nasdaq compliance after equity shortfall notice
On April 30, 2025, Nasdaq notified ABVC that stockholders' equity of $723,959 as of April 23 failed Listing Rule 5550(b)(1).
ABVC BioPharma says 2023 financials error resolved in filed 10-K, no amendment needed
Original 8-K on Apr 15, 2025 flagged 2023 financials for errors, requiring amendment.
ABVC BioPharma Q1 net loss narrows 68% to $944K; eyes AI agriculture in Taiwan
Net loss per share improved to $(0.06) from $(0.29) in Q1 2024.
ABVC receives Nasdaq delisting notice for low equity; raises $436K in stock sale
Nasdaq notified ABVC on April 24 that stockholders' equity of $723,959 is below the $2.5M minimum for continued listing.
ABVC FY2024 revenue $509.6K (+234%), net loss narrows 77% to $4.9M, EPS $(0.42)
Revenue surged 234% to $509,589 driven by licensing milestones.
ABVC BioPharma reports 2024 revenue up 234%, EPS improves 77%, but restates FY2023 financials
Revenue $509,589 (+234% YoY); net loss narrowed to $4.90M; EPS improved 77% to ($0.42).
CFO Leeds Chow resigns; CEO Uttam Patil named interim CFO
Leeds Chow resigned as CFO of ABVC Biopharma effective March 5, 2025.
ABVC BioPharma granted additional 180-day Nasdaq bid price compliance extension to July 7, 2025
Nasdaq extended deadline from January 6, 2025 to July 7, 2025 for minimum $1.00 bid price requirement.
ABVC BioPharma agrees to reduce warrant exercise price to $0.40 for 1.03M shares, raising $412k
Lind Global Fund exercises 1,029,167 warrants at reduced price of $0.40/share, generating $411,666.80 in proceeds.
ABVC BioPharma Q3 revenue $389K, net loss narrows to $134K; first operational profit
Revenue of $389,276 in Q3 2024 vs $15,884 in Q3 2023, a 2,350% increase.
ABVC BioPharma induces Lind Global to exercise 500,000 warrants at $0.42/share
Lind exercises 500,000 existing warrants at reduced price of $0.42/share, generating approx. $210,000 in cash.
ABVC BioPharma auditor WWC P.C. declines renewal; Simon & Edward LLP appointed
WWC agreed not to renew engagement effective Oct 10, 2024; Board approved non-renewal on Oct 17.
ABVC Biopharma regains compliance with Nasdaq Shareholder Approval Rules
Received Nasdaq notification on Sept 6, 2024 confirming compliance with Listing Rules 5635(a)(1) and 5635(a)(2).
ABVC BioPharma updates corporate presentation; no material new details disclosed
Company filed Form 8-K furnishing an updated corporate presentation on August 20, 2024.
ABVC BioPharma Q2 2024 EPS improves 86.8% to -$0.09; licensing deals worth up to $292M
EPS improved 86.8% YoY to -$0.09 in Q2 2024 from -$0.68; revenue surged to $117,142 from $6,109.
ABVC BioPharma CFO suspends work amid salary dispute; company corrects license fee numbers downward
CFO Leeds Chow suspends work due to disagreements over salary owed; CEO Uttam Patil becomes interim CFO.
ABVC BioPharma receives Nasdaq deficiency notice for bid price below $1.00
Received Nasdaq notice on July 10, 2024 for non-compliance with minimum $1.00 bid price rule over 30 consecutive days.
ABVC BioPharma amends licensing deal to allow $3.5M milestone paid incrementally
On June 23, 2024, ABVC and BioLite amended licensing agreements with AiBtl BioPharma for CNS drugs MDD and ADHD.
ABVC BioPharm amends ophthalmology license deal to allow incremental milestone payments
ABVC and BIOFIRST amended licensing agreement with ForSeeCon Eye Corp (FEYE) covering ophthalmology pipeline including Vitargus.
ABVC licenses MDS drug BLEX 404 to OncoX; eligible for $13.75M in fees plus royalties
ABVC and subsidiary BioLite grant OncoX exclusive rights to develop/commercialize BLEX 404 for MDS in 50% of global markets for 20 years.
ABVC Biopharma induces Lind Global to exercise 1M warrants at $0.75, issues new 1M warrant at $1.00
Lind Global exercises 1,000,000 existing warrants at reduced price of $0.75/share, generating $750,000 cash proceeds.
ABVC BioPharma terminates land transfer agreement with director Shuling Jiang
Board terminated agreement to acquire land in Taoyuan City, Taiwan from director Shuling Jiang on May 16, 2024.
ABVC BioPharma licenses BLEX 404 for TNBC to OncoX in deal worth up to $13.75M plus royalties
Definitive license agreement with OncoX BioPharma for exclusive rights to develop and commercialize BLEX 404 for TNBC in 50% of worldwide markets for 20 years.
ABVC licenses BLEX 404 to OncoX for pancreatic cancer; up to $13.75M in fees plus royalties
ABVC grants OncoX exclusive rights to develop/commercialize BLEX 404 for pancreatic cancer in 50% of worldwide markets for 20 years.
All 11 director nominees were re-elected; quorum of 5,736,015 shares (54.31%) represented.
License for ABVC's single-herb botanical extract from Maitake Mushroom (BLEX 404) for NSCLC in North America for 20 years.
20-year exclusive global license with ForSeeCon Eye Corp for ophthalmology pipeline including Vitargus.
ABVC BioPharma FY2023 revenue falls 84% to $152K; net loss narrows to $10.9M
Revenue of $152,430 in FY2023, down from $969,783 in FY2022; net loss improved 31% to $10.9M.
ABVC BioPharma amends bylaws to reduce shareholder quorum to 33-1/3%
Board approved amendment to Section 2.8 of Bylaws on March 14, 2024.
ABVC BioPharma amends convertible note with Lind: imposes $1 floor conversion price
Amendment to $1.2M secured convertible note sets conversion floor at $1.00, per Nasdaq requirements.
ABVC BioPharma amends convertible note with $1.00 floor price; cash payment on floor conversions
Amendment to $1M secured convertible note sets floor conversion price at $1.00 per share.
ABVC BioPharma acquires $2.96M Taiwan land via stock & warrants in related-party deal
Land valued at ~$2.96M; consideration is 703,495 restricted shares at $3.50/share plus 5-yr warrants for 1M shares at $2.00.
On March 5, 2025, Mr. Leeds Chow, the Chief Financial Officer (“CFO”) of ABVC BioPharma, Inc. (the “Company”) notified the Company of his resignation as CFO.
While the Company is looking for a full-time Chief Financial Officer to fill the vacancy created by Leeds Chow’s resignation, the Company’s CEO, Uttam Patil will serve as the interim Chief Financial Officer of the Company.
due to disagreements regarding salaries due and payable, Mr. Chow has informed the Company that he is suspending his work as CFO.
The Company’s CEO, Uttam Patil, will assume the duties of interim Chief Financial Officer until the parties settle the disagreement and Leeds resumes his position as CFO.
Max materiality 0.90 · Median 0.60 · Most common event other_material